Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1955 1
1956 1
1957 1
1959 1
1960 2
1961 2
1962 3
1963 4
1964 6
1965 21
1966 10
1967 10
1968 10
1969 9
1970 7
1971 17
1972 17
1973 15
1974 24
1975 19
1976 16
1977 22
1978 26
1979 25
1980 38
1981 37
1982 51
1983 61
1984 60
1985 56
1986 65
1987 68
1988 56
1989 73
1990 57
1991 57
1992 64
1993 85
1994 105
1995 91
1996 112
1997 104
1998 152
1999 133
2000 133
2001 120
2002 149
2003 142
2004 122
2005 121
2006 135
2007 143
2008 130
2009 140
2010 185
2011 186
2012 234
2013 216
2014 210
2015 191
2016 181
2017 202
2018 231
2019 249
2020 295
2021 342
2022 265
2023 231
2024 126

Text availability

Article attribute

Article type

Publication date

Search Results

5,888 results

Results by year

Filters applied: . Clear all
Page 1
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, Okumura N, Yamaguchi M, Ikeda N, Wakabayashi M, Nakamura K, Fukuda H, Nakamura S, Mitsudomi T, Watanabe SI, Asamura H; West Japan Oncology Group and Japan Clinical Oncology Group. Saji H, et al. Among authors: okada m. Lancet. 2022 Apr 23;399(10335):1607-1617. doi: 10.1016/S0140-6736(21)02333-3. Lancet. 2022. PMID: 35461558 Clinical Trial.
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group. Aokage K, et al. Among authors: okada m. Lancet Respir Med. 2023 Jun;11(6):540-549. doi: 10.1016/S2213-2600(23)00041-3. Epub 2023 Mar 6. Lancet Respir Med. 2023. PMID: 36893780 Clinical Trial.
Treatment for secondary hyperparathyroidism focusing on parathyroidectomy.
Hiramitsu T, Hasegawa Y, Futamura K, Okada M, Goto N, Narumi S, Watarai Y, Tominaga Y, Ichimori T. Hiramitsu T, et al. Among authors: okada m. Front Endocrinol (Lausanne). 2023 Apr 20;14:1169793. doi: 10.3389/fendo.2023.1169793. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37152972 Free PMC article. Review.
Renal hyperparathyroidism.
Yajima A, Tsuchiya K, Kuro-O M, Urena P, Tominaga Y, Okada M, Ichimori T, Tomosugi T, Hiramitsu T, Murata T, Nakamura M, Sasaki M, Ito A, Nitta K. Yajima A, et al. Among authors: okada m. Vitam Horm. 2022;120:305-343. doi: 10.1016/bs.vh.2022.04.010. Epub 2022 Jul 22. Vitam Horm. 2022. PMID: 35953115
The lysosomal Ragulator complex activates NLRP3 inflammasome in vivo via HDAC6.
Tsujimoto K, Jo T, Nagira D, Konaka H, Park JH, Yoshimura SI, Ninomiya A, Sugihara F, Hirayama T, Itotagawa E, Matsuzaki Y, Takaichi Y, Aoki W, Saita S, Nakamura S, Ballabio A, Nada S, Okada M, Takamatsu H, Kumanogoh A. Tsujimoto K, et al. Among authors: okada m. EMBO J. 2023 Jan 4;42(1):e111389. doi: 10.15252/embj.2022111389. Epub 2022 Nov 29. EMBO J. 2023. PMID: 36444797 Free PMC article.
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K, Doki Y, Ogata T, Motoyama S, Kawakami H, Ueno M, Kojima T, Shirakawa Y, Okada M, Ishihara R, Kubota Y, Amaya-Chanaga C, Chen T, Matsumura Y, Kitagawa Y. Kato K, et al. Among authors: okada m. Esophagus. 2023 Apr;20(2):291-301. doi: 10.1007/s10388-022-00970-1. Epub 2022 Nov 19. Esophagus. 2023. PMID: 36401133 Free PMC article. Clinical Trial.
Aortite chez une patiente recevant une chimiothérapie.
Fukui S, Kidoguchi G, Okada M. Fukui S, et al. Among authors: okada m. CMAJ. 2023 Feb 27;195(8):E315-E316. doi: 10.1503/cmaj.220584-f. CMAJ. 2023. PMID: 36849171 Free PMC article. French. No abstract available.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: okada m. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Clinical Trial.
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Sugawara S, Tanaka K, Imamura F, Yamamoto N, Nishio M, Okishio K, Hirashima T, Tanaka H, Fukuhara T, Nakahara Y, Kurata T, Katakami N, Okada M, Horinouchi H, Udagawa H, Kasahara K, Satouchi M, Saka H, Tokito T, Hosomi Y, Aoe K, Kishi K, Ohashi K, Yokoyama T, Adachi N, Noguchi K, Schwarzenberger P, Kato T. Sugawara S, et al. Among authors: okada m. Cancer Sci. 2023 Aug;114(8):3330-3341. doi: 10.1111/cas.15816. Epub 2023 May 15. Cancer Sci. 2023. PMID: 37183528 Free PMC article. Clinical Trial.
5,888 results